New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;FB;PMFG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
March 5, 2015
06:58 EDTBMYBristol-Myers price target raised to $75 from $70 at JPMorgan
JPMorgan raised its price target for shares of Bristol-Myers to $75 after the company received FDA approval of Opdivo in lung cancer earlier than expected. The firm sees "rapid adoption" of the drug and notes Bristol has a number of pipeline catalysts remaining in 2015. It reiterates an Overweight rating on the stock.
05:52 EDTFBInstagram announces new advertising format called carousel ads
Instagram is offering a new advertising format called carousel ads that allows marketers to include links on their products and websites. In a blogpost, the company said, "One way to look at it is carousel ads bring the potential of multi-page print campaigns to mobile phones – with the added benefit of taking people to a website to learn more. For instance, a fashion company could use the carousel to deconstruct the individual products in a ‘look.’ A car company might share an array of different features of a vehicle and provide a link to learn more about the new model. Or, an advertiser could showcase how multiple ingredients come together to make a delicious meal." The format will be introduced on a limited basis. Reference Link
March 4, 2015
17:11 EDTBMYOn The Fly: Closing Wrap
Subscribe for More Information
16:17 EDTBMYBristol-Myers reports FDA approval of Opdivo
Subscribe for More Information
16:02 EDTFB, BMYOptions Update; March 4, 2015
iPath S&P 500 VIX Short-Term Futures down 6c to 27.22. Option volume leaders: AAPL TSLA TWTR AA PBR NFLX MNKD FB BMY C according to Track Data.
14:28 EDTBMYBristol-Myers announces FDA approval of added Opdivo indication
Subscribe for More Information
13:58 EDTBMYBristol-Myers jumps 4% to $64.23 after FDA approves Opdivo for lung cancer
Subscribe for More Information
13:40 EDTBMYFDA expands use of Opdivo to treat lung cancer
Subscribe for More Information
07:45 EDTFBFacebook developing rival to Twitter ad platform, Bloomberg says
Subscribe for More Information
06:14 EDTFBFacebook implied volatility of 24 at lower end of index mean range
Subscribe for More Information
05:25 EDTBMYBristol-Myers signs exclusive agreement with Bavarian Nordic for Prostvac
Bavarian Nordic and Bristol-Myers Squibb announced an agreement that provides Bristol-Myers Squibb an exclusive option to license and commercialize Prostvac, Bavarian Nordic’s investigational Phase 3 prostate-specific antigen, or PSA,-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer, or mCRPC. Under terms of the agreement, Bavarian Nordic will receive an upfront payment of $60M. Bristol-Myers Squibb can exercise the option in its sole discretion within a designated time after data is available from the ongoing Phase 3 trial. Bavarian Nordic would be entitled to a payment of $80M upon exercise of the option plus additional incremental payments starting at $50M, but with a potential to exceed $230M should the median overall survival benefit of Prostvac exceed the efficacy seen in Phase 2 results. Furthermore, Bavarian Nordic could receive regulatory milestone payments of $110M, up to $495M in sales milestones as well as tiered double-digit royalties on future sales of Prostvac. The parties have also agreed to enter into a supply contract, under which Bavarian Nordic will undertake the future commercial manufacturing of Prostvac. An investigator sponsored Phase 2 study is currently in the planning stages to investigate the combination of Bristol-Myers Squibb’s Yervoy and Prostvac. The companies have also entered into an agreement by which they may conduct one or more exploratory combination studies of Prostvac and agents from Bristol-Myers Squibb’s immuno-oncology portfolio.
March 3, 2015
11:46 EDTBMYLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
07:21 EDTFBOculus hires away Google executive Mary Lou Jepsen, Re/code says
Facebook's (FB) Oculus has hired away Google (GOOG) executive Mary Lou Jepsen, reports Re/code, citing sources familiar with the move and a Facebook spokesperson. Jepsen was the head of Google X's display division. Reference Link
07:16 EDTBMYCowen to hold a conference
35th Annual Health Care Conference is being held in Boston on March 2-4 with webcasted company presentations to begin on March 3 at 8 am; not all company presentations may be webcasted. Webcast Link
06:02 EDTBMYBristol-Myers reports hepatitis C cure rate of 97% in study
A combination of two once-daily medications for chronic hepatitis C infection has been shown in newly released study results to cure almost all the patients who participated, despite the patients also being co-infected with HIV. This patient population historically has been challenging to treat for hepatitis C, in large part due to potential drug-drug interactions between the antiviral therapy regimens used to treat each infection. Results of ALLY-2, a Phase 3 clinical trial evaluating the investigational once-daily combination of daclatasvir and sofosbuvir for the treatment of chronic hepatitis C in patients co-infected with HIV were announced last week and showed that those treated for 12 weeks, 97% achieved cure. The ALLY-2 study met the primary endpoint, with 96% of treatment-naïve genotype 1 patients achieving SVR12. Treatment with daclatasvir in combination with sofosbuvir in this study showed high SVR rates, with no discontinuations due to adverse events, and no serious adverse events related to study medications throughout the treatment phase. In ALLY-2, high SVR rates occurred among all patients treated for 12 weeks, regardless of prior treatment experience, HCV genotype, cirrhosis status, concurrent combination antiretroviral therapy regimen, or race. ALLY-2 also included an 8-week arm; 38 of 50 treatment-naïve patients with HCV achieved SVR12. However, study investigators concluded that further studies are needed to assess the potential of shorter-duration, all-oral treatment regimens.
March 2, 2015
13:53 EDTFBFacebook COO: Working on simplifying buying process for ads
Subscribe for More Information
13:42 EDTFBFacebook COO: Small business opportunity is huge
Subscribe for More Information
13:29 EDTFBFacebook COO: Facebook is moving towards more public usage
Says mobile paying off in "a big way." Says ads integrate very well into mobile. Says video is "exploding on Facebook" and provides huge ad opportunities. Says not all video ads are "incremental." Sheryl Sandberg is speaking at the Morgan Stanley Technology, Media & Telecom Conference.
13:22 EDTFBFacebook CFO: Messaging is core to company's strategy
Subscribe for More Information
13:19 EDTFBFacebook CFO: We are investing from a 'position of strength'
Subscribe for More Information
10:08 EDTFBStocks with call strike movement; HLF FB
Subscribe for More Information
10:00 EDTFBOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:28 EDTBMYBristol-Myers says FDA accepts Yervoy sBLA for review
Subscribe for More Information
09:11 EDTFBFacebook initiated with a Buy at Axiom
Subscribe for More Information
08:29 EDTFBMicrosoft reportedly to buy news app for $30M, TechCrunch says
Subscribe for More Information
07:41 EDTFBMorgan Stanley to hold a conference
Subscribe for More Information
07:20 EDTBMYCowen to hold a conference
Subscribe for More Information
06:56 EDTFBIAC's Tinder working on first ads, Re/code reports
IAC's Tinder is developing its first ad product, Re/code reported Friday night. The dating app is also talking with Facebook (FB) and Twitter (TWTR) about using their ad networks to fill out ad space, Re/code stated. Reference Link
February 27, 2015
13:35 EDTBMYBristol-Myers reports FDA accepts BLA for Opdivo
Subscribe for More Information
08:29 EDTBMYBristol-Myers price target raised to $78 from $70 at Argus
Subscribe for More Information
05:57 EDTFBFacebook implied volatility of 24 at lower end of index mean range
Subscribe for More Information
February 26, 2015
15:23 EDTBMYBristol-Myers reports ALLY trial demonstrates 97% hepatitis C cure rates
Subscribe for More Information
13:25 EDTFBGerman watchdog issues cease-and-desist letter to Facebook, WSJ says
Subscribe for More Information
12:12 EDTFBFacebook climbs after analyst says Oculus could be used for NBA, NHL games
Subscribe for More Information
10:41 EDTFBFacebook retakes the $80 level, runs higher, levels to watch
Subscribe for More Information
09:35 EDTFBActive equity options trading on open
Subscribe for More Information
08:35 EDTBMYBristol-Myers says BMS-966176 Phase IIa study met primary endpoint
Subscribe for More Information
February 25, 2015
19:46 EDTFBFacebook's Oculus a significant long term opportunity, says Piper Jaffray
Subscribe for More Information
08:36 EDTBMYBristol-Myers announces data from Phase IIb BMS-663068 trial
Bristol-Myers Squibb Company announced data from a Phase IIb trial of investigational compound BMS-663068, designed as an HIV-1 attachment inhibitor, in treatment-experienced HIV-1 patients. In the study, which compared BMS-663068 to a pharmacoenhanced protease inhibitor, virologic response rates and immunologic reconstitution were similar across the BMS-663068 and Reyataz/ritonavir arms of the trial through 48 weeks. Specifically, 61-82% of BMS-663068 patients had HIV-1 RNA levels <50 c/mL, compared to 71% of Reyataz/ritonavir patients at week 48. HIV-1 RNA levels <50 c/mL typically indicate virus replication is undetectable. Treatment with BMS-663068 resulted in no dose response safety signals, no treatment discontinuations related to adverse events, and no treatment-related serious adverse events over the course of the trial. The most common AEs were headache and abdominal pain. Due to the positive results seen thus far, a Phase III clinical trial of the attachment inhibitor among heavily treatment-experienced patients began on Monday, February 23, 2015. For the purposes of the Phase III trial, heavily treatment-experienced patients are defined as individuals who can no longer formulate a viable regimen due to accumulation of drug resistance, past intolerabilities or antiretroviral contraindications. The Phase IIb study results, presented yesterday at the 22nd Conference on Retroviruses and Opportunistic Infections, highlight the novel mechanism of action of the investigational prodrug BMS-663068, which when converted into its active moiety BMS-626529, is designed to bind directly to the HIV gp120 protein, and prevents initial viral attachment to the host CD4+ T cell and entry into the host immune cell.
05:56 EDTFBFacebook implied volatility of 25 at lower end of index mean range
Subscribe for More Information
February 24, 2015
09:40 EDTFBFacebook says over 2M advertisers now active, launches Ads Manager app
There are now more than 2 million active advertisers on Facebook, the company announced. Facebook also announced the launch of Ads Manager, a new mobile app that gives marketers more power to manage ads from anywhere. Reference Link
07:46 EDTBMYJacobs Engineering awarded contract from Bristol-Myers
Jacobs Engineering Group (JEC) announced that it received a contract from Bristol-Myers Squibb Company (BMY) to provide architectural and engineering services for a new large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland. The facility is being designed to produce multiple therapies for the company’s robust and growing portfolio of approved and investigational biologic medicines, and to increase Bristol-Myers Squibb’s biologics manufacturing capacity. The new facility is expected to include multiple large scale bioreactors, a purification area, as well as office and laboratory space. Bristol-Myers Squibb’s Board of Directors has approved initial funding that will support the first phase of the project, with the full cost of the facility expected to be finalized in the second half of 2015. The facility is estimated to be operational in 2019.
06:08 EDTFBFacebook implied volatility of 25 at lower end of index mean range
February 23, 2015
16:00 EDTFBOptions Update; February 23, 2015
Subscribe for More Information
12:21 EDTBMYOn The Fly: Midday Wrap
Subscribe for More Information
09:48 EDTFBFacebook experiencing likely service disruption, downrightnow says
Subscribe for More Information
09:39 EDTFBActive equity options trading on open
Subscribe for More Information
09:14 EDTFBBelgian commissioned study finds Facebook privacy policy violates European law
Subscribe for More Information
08:15 EDTBMYRigel Pharmaceuticals and Bristol-Myers announces R&D collaboration agreement
Rigel Pharmaceuticals (RIGL) and Bristol-Myers (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system's activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibb's Opdivo and Yervoy. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel's TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
08:06 EDTBMYBristol-Myers, Rigel enter R&D agreement for TGF beta receptor kinase inhibitors
Rigel Pharmaceuticals (RIGL) and Bristol-Myers Squibb (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel’s extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system’s activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibb’s Opdivo, or nivolumab, and Yervoy, or ipilimumab. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel’s TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
08:01 EDTBMYBristol-Myers to acquire Flexus, potential total consideration may be $1.25B
Subscribe for More Information
06:21 EDTFBFacebook's shuttle drivers approve new union contract, WSJ reports
Subscribe for More Information
06:14 EDTFBFacebook implied volatility of 25 at lower end of index mean range
Subscribe for More Information
February 20, 2015
16:03 EDTFBOptions Update; February 20, 2015
Subscribe for More Information
09:38 EDTFBActive equity options trading on open
Subscribe for More Information
07:23 EDTBMYAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
05:21 EDTFBFacebook implied volatility of 25 at lower end of index mean range
February 19, 2015
16:01 EDTFBOptions Update; February 19, 2015
iPath S&P 500 VIX Short-Term Futures down 70c to 30.11. Option volume leaders: AAPL TSLA TWTR AMAT PBR KO FB AXP NFLX according to Track Data.
11:47 EDTFBFacebook breaks above its 50-day moving average
Subscribe for More Information
11:40 EDTFBFacebook rises after analyst pegs Instagram value at $33B
Subscribe for More Information
09:35 EDTFBOption volume leaders
Option volume leaders: AAPL TSLA TWTR MCD WMT PBR SPWR WFM GILD FB SCTY according to Track Data.
07:58 EDTFBFacebook remains a top pick for 2015, says Cowen
Subscribe for More Information
06:17 EDTFBFacebook Seattle gets new office, 1500 hires in 2016, TechFlash says
Subscribe for More Information
05:36 EDTFBFacebook implied volatility of 25 at lower end of index mean range
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use